Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis

Kevin R. Flaherty, Martin Kolb, Carlo Vancheri, Wenbo Tang, Craig S. Conoscenti, Luca Richeldi

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

In the Phase III INPULSIS® trials, nintedanib reduced the annual rate of decline in forced vital capacity (FVC) versus placebo in patients with idiopathic pulmonary fibrosis (IPF). We conducted post hoc analyses of the distribution of changes in FVC in the INPULSIS® trials and FVC changes in the open-label extension trial INPULSIS®-ON in subgroups of patients based on whether patients had shown an improvement or no decline in FVC in INPULSIS®. Analyses were descriptive. Based on the annual rate of change in FVC, 158 of 638 patients (24.8%) treated with nintedanib and 38 of 423 patients (9.0%) treated with placebo had an improvement/no decline in FVC in the INPULSIS® trials. In patients whose FVC improved/did not decline, median (interquartile range) improvements in FVC at week 52 were 76.5 (31-152) mL and 57.5 (31-103) mL in the nintedanib and placebo groups, respectively. Changes in FVC from baseline to week 48 of INPULSIS®-ON were similar in patients whose FVC improved or declined in the preceding INPULSIS® trial. In the INPULSIS® trials, treatment with nintedanib resulted in a greater proportion of patients with IPF showing an improvement/no decline in FVC compared to taking placebo. Mechanisms underlying improvement in FVC in patients with IPF are unknown.
Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalEuropean Respiratory Journal
Volume52
DOIs
Publication statusPublished - 2018

Keywords

  • Aged
  • Enzyme Inhibitors
  • Female
  • Follow-Up Studies
  • Humans
  • Idiopathic Pulmonary Fibrosis
  • Indoles
  • Lung
  • Male
  • Middle Aged
  • Severity of Illness Index
  • Treatment Outcome
  • Vital Capacity
  • Weight Loss

Fingerprint

Dive into the research topics of 'Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis'. Together they form a unique fingerprint.

Cite this